Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...
Racura Oncology’s lead drug candidate RC220 has cleared an important regulatory hurdle after receiving governance approval from Monash Health to start a phase I clinical trial in patients with ...